Jubilant Pharmova Ltd (JUBLPHARMA) — Announcement | 28 August 2026

· BSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Jubilant Pharmova receives GST show cause notice from CGST Roorkee
💡 Investor Takeaway
The notice poses no expected financial or operational risk to the company.

Jubilant Pharmova disclosed receipt of a GST show cause notice from the Joint Commissioner of CGST, Roorkee, dated August 27, 2026, demanding ₹52.75 Cr in IGST refund, interest, and penalty for FY 2020-21 and 2021-22 related to Rule 96 violations. The company contests the notice as legally incorrect and expects no financial or operational impact, filing a detailed reply shortly.

📄 View Original Announcement (PDF)

About Jubilant Pharmova Ltd (JUBLPHARMA)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹14,469.9 Cr P/E: 40.9 ROE: 5.0% ROCE: 7.4% Div Yield: 0.55%

View full JUBLPHARMA stock details →

📡 Get AI alerts when JUBLPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track JUBLPHARMA — Free

📊 More JUBLPHARMA filings

See all JUBLPHARMA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when JUBLPHARMA files new disclosures

Track JUBLPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track JUBLPHARMA — Free

Free account · 2 AI queries/day